Prudential Financial
YMAB

Prudential Financial’s Y-mAbs Therapeutics YMAB Stock Holding History

Prudential Financial’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,625
Closed -$146K – 2394
2024
Q4 		$146K Sell
18,625
-12,000
-39% -$146K ﹤0.01% 2120
2024
Q3 		$403K Sell
30,625
-32,100
-51% -$407K ﹤0.01% 2302
2024
Q2 		$758K Sell
62,725
-2,435
-4% -$32.9K ﹤0.01% 1985
2024
Q1 		$1.06M Sell
65,160
-48,490
-43% -$654K ﹤0.01% 1806
2023
Q4 		$775K Sell
113,650
-172,200
-60% -$996K ﹤0.01% 1942
2023
Q3 		$1.56M Buy
285,850
+35,900
+14% +$209K ﹤0.01% 1519
2023
Q2 		$1.7M Buy
249,950
+175,900
+238% +$1.32M ﹤0.01% 1515
2023
Q1 		$371K Buy
74,050
+50,900
+220% +$208K ﹤0.01% 2201
2022
Q4 		$113K Buy
+23,150
New +$168K ﹤0.01% 2448

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Prudential Financial's YMAB Position: Q1 2025 in Review

Prudential Financial sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 18,625 shares — an estimated $146K sold.

Prudential Financial first reported a position in YMAB in Q4 2022 and held it in 9 quarters. The position peaked at $1.7M in Q2 2023. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Prudential Financial reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Prudential Financial sold 18,625 Y-mAbs Therapeutics shares in Q1 2025, an estimated $146K.
  • Prudential Financial first reported a position in Y-mAbs Therapeutics in Q4 2022 and held it in 9 quarters.
  • Prudential Financial's Y-mAbs Therapeutics position peaked at $1.7M in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Prudential Financial's 13F filing for Q1 2025, filed 13 May 2025.